# **Special Issue**

# Tumor-Resident Microbes and Small Molecular Anti-Cancer Drugs in Tumor Microenvironment

## Message from the Guest Editor

The tumor-resident microbiota and some small molecular anti-cancer drugs are associated with the development and progression of cancer, and manipulation of the tumor-resident microbiota is a novel strategy for the prevention and treatment of cancer. Some microbita have antitumor activity against cancer, improving the tumor microenvironment, activating immune cells including dendritic cells, helper T cells, natural killer cells, and cytotoxic T cells, and upregulating the secretion of pro-tumor immune cytokines such as interleukin-2 and interferon. Tumor-resident microbiota and some metabolites are involved in anticancer drug design and targeted delivery.

### **Guest Editor**

Dr. Chenglai Xia

School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China

### Deadline for manuscript submissions

closed (30 June 2024)



# **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



### mdpi.com/si/176044

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/ molecules





# **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

### **Editor-in-Chief**

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

